Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings
Optomed Plc Stock Exchange Release 5 June 2023 at 13.30, Helsinki
Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings
Optomed Plc (“Optomed” or the “Company”) has received a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the “SMA”) from Cenova Capital (“Notifier”). According to the notification, the total holdings in Optomed shares and votes held by Notifier through its funds (Shanghai Cenova Innovation Venture Fund (Limited Partnership), Alnair Investment and Cenova China Healthcare Fund IV, L.P.) has decreased to 9.96 per cent of all of the registered shares in Optomed on 2 June 2023.
The total number of the Company’s registered shares amounts to 16,541,355 shares. Each share entitles to one vote.
The total position of Notifier subject to the notification:
|
|
% of shares and voting rights (total of A) |
% of shares and voting rights through financial instruments (total of B) |
Total of both in % (A+B) |
|
Resulting situation on the date on which threshold was crossed or reached |
9.96 % |
- |
9.96 % |
|
Position of previous notification (if applicable) |
14.36 % |
- |
14.36 % |
Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
|
Class/type of shares
ISIN code |
Number of shares and voting rights |
% of shares and voting rights |
||
|
Direct |
Indirect |
Direct |
Indirect |
|
|
FI4000410881 |
1,647,771 |
- |
9.96 % |
- |
|
SUBTOTAL A |
2,211,664 |
9.96 % |
||
Information in relation to the person subject to the notification obligation as contained in the notification
The complete chain of controlled undertakings through which the shares, voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
|
Name |
% of shares and voting rights |
% of shares and voting rights through financial instruments |
Total of both |
|
Cenova China Healthcare GP IV Limited |
0% of shares and 100% voting rights |
- |
0% of shares and 100% voting rights of Cenova China Healthcare Fund IV, L.P |
|
Shanghai Cenova Bioventure Equity Investment Fund Management Enterprise |
1% of shares and 100% voting rights |
- |
1% of shares and 100% voting rights of Shanghai Cenova Innovation Venture Fund (Limited Partnership) |
|
Shanghai Cenova Innovation Venture Fund (Limited Partnership) |
100% |
- |
100% of Alnair Investment |
Further enquiries
Sakari Knuutti, CFO, Optomed Plc, sakari.knuutti@optomed.com
www.optomed.com
Optomed in Brief
Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld screening devices fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries.